Novartis’ TOBI Podhaler: Can Patient Satisfaction Overcome FDA’s Clinical Concerns?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA seems to find the data from the pivotal trials of the inhalation powder drug-device combination for the management of cystic fibrosis patients with Pseudomonas aeruginosa something less than persuasive.